The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...

Analysts were expecting the treatment to achieve an average weight loss of about 20% to 25% after one year of treatment, ...

Amgen stock was dropping in premarket trading after releasing data from a Phase 2 study for its experimental weight-loss drug ...

Amgen (NASDAQ:AMGN) today announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide ...

According to phase 2 study, MariTide achieved significant weight loss in individuals with obesity or overweight, with up to ...

Amgen released promising results from its Phase 2 trial, but the data led to a significant decline in its stock price as Wall ...

With Amgen’s MariTide results at the lower end of investors’ expectation of 20% to 25% weight loss, the much-anticipated ...

Amgen's experimental weight loss injection, MariTide, showed up to 20% weight loss in patients without diabetes and 17% in ...

Amgen's latest once-monthly weight loss drug data looks "OK," analysts say, as its path to approval still remains murky.

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.